Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-06
2007-02-06
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000
Reexamination Certificate
active
08465455
ABSTRACT:
Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.
REFERENCES:
patent: 3161565 (1964-12-01), Vigneron
patent: 3868451 (1975-02-01), Stein et al.
patent: 4027017 (1977-05-01), Hata et al.
patent: 4058601 (1977-11-01), Hata et al.
patent: 4613604 (1986-09-01), Chu et al.
patent: 4757139 (1988-07-01), Kawaguchi et al.
patent: 4874602 (1989-10-01), Calabresi et al.
patent: 5077280 (1991-12-01), Sommadossi et al.
patent: 5141943 (1992-08-01), Naguib et al.
patent: 5298487 (1994-03-01), Chen et al.
patent: 27226/88 (1989-05-01), None
patent: 22544/92 (1993-01-01), None
patent: 339075 (1989-11-01), None
patent: 355131 (1990-02-01), None
patent: 0 358 008 (1990-03-01), None
patent: 1 297 398 (1972-11-01), None
patent: 60-174797 (1984-02-01), None
patent: 2-500372 (1990-02-01), None
patent: 03/135918 (1991-06-01), None
patent: 3-169815 (1991-07-01), None
patent: WO 85/00608 (1985-02-01), None
patent: WO80/03837 (1989-05-01), None
patent: WO80/03838 (1989-05-01), None
patent: WO 89/03837 (1989-05-01), None
patent: WO 89/03838 (1989-05-01), None
patent: 94/13687 (1994-06-01), None
patent: WO 94/13687 (1994-06-01), None
Baker et al., American J. of Medicine, vol. 82(3), 1987.
Aderka et al, “Med Hypotheses”, (1988), 27:193-6.
Arai M. et al, “Hepatology” (1989) 9:846-851.
Bowers et al., “J. Surg. Res.” (1989) 47:183-8.
Cerra et al, in “Molecular and Cellular Mechanisms of Septic Shock” 265-277, Alan R. Liss (1989).
Clark et al, “Am. J. Pathol.” (1987), 129:192-9.
Echtenacher et al, “J. Immunol.” 145:3762-3766 (1990).
Engelhardt, R. et al, “Cancer. Res.” (1991), 51:2524-30.
Farrar and Corwin, Ann. “N.Y. Acad. Sci.” 133:668-684 (1966).
Galanos et al, “PNAS”, 76:5939-5943, (1979).
Gut et al, “J. Infect. Disease.” (1984) 149:621.
Halacheva et al, “Toxicon” (1988), 26:571-576.
Havell, “J. Immunol.” 139:4225-4231 (1987).
Kang et al, “J. Histochem. Cytochem.” (1988), 36:665-678.
Kilpatrick et al, “Metabolism” (1989) 38:73-7.
Kimura et al, “Cancer, Chemother, Pharmacol” (1987); 20:223-9.
Lomanto et al, “Anesth. Analg.” (1972), 51:264-270.
Markley et al, “J. Trauma” 10:598-607, (1970).
McClain CJ and Cohen DA, “Hepatology” (1989) 9:349-351.
Nolan JP, “Gastroenterology” 69:1346-1356 (1975).
Nolan, JP, “Hepatology” (1989), 10:887-91.
Nolan JP and Leibowitz AI, “Gastroenterology” (1978), 75:445-9.
O'Sullivan, “Aust. N.Z. J. Med.”, (1973) 3:417-422.
Pappo et al, “J. Surg. Res.” (1991) 51:106-12.
Pates et al, “Farmakol Toksikol” (1968), 31:717-719.
Rosenthal et al, “Toxicology” 56:239-251 (1989).
Seljelid, “Scand. J. Immunol.” (1989), 29:181-92.
Shafer et al “Gastroenterology” (1961), 40:782-784.
Shirai et al“Acta Pathol. Jpn.” (1987) 37:1127-1134.
Taki et al “Eur. Surg. Res.” (1985), 17:140-9.
Tiegs et al “J. Clin. Invest.” (1992) 90:196-203.
Van Bladel et al “Cytokine” (1991) 3:149-54.
van Groeningen et al “Proceedings of the AACR” (1987), 28:195.
Van Groeningen et al “Cancer Tret Rep.” (1986), 70:745-50.
Viens et al “J. Immunother” (1992), 11:218-24.
Von Euler et al “J. Biol. Chem.” (1963), 238:2464-2469.
Wang et al “Arch. Surg.” (1991), 126:219-224.
Lehninger, Albert L., “Biochemistry” Second Edition, Worth Publishers, Inc. New York, 1975, pp. 735-736.
—Martin et al., J. Pharm. Sci., V. 76, No. 2 (Feb. 1987) p. 180-183 “Synthesis And Antiviral Activity of Various Esters of 9-[1,3-Dihydroxy-2-propoxy)methyl]guanine.”
—Casida et al, Biochemical Pharmacology, V. 15, (1966) p. 627-644 “3′,5′-Diesters of 5-Fluoro-2′-Deoxyuridine and Thymidine: Hydrolysis by Esterases in Human, Mouse, and Insect Tissue.”
—Ensminger et al, Biochemical Pharmacology, V. 28 (1979) p. 1541-1545 “Thymidine 5′-O-Pivaloate: A Prodrug Derivative of Thymidine with Potential Applications in High-Dose Methotrexate Therapy.”
—Martin et al, Cancer Research, V. 42 (Oct. 1982) p. 3964-3970 “High-Dose 5-Fluorouracil with Delayer Uridine ‘Rescue’ in Mice.”
Derwent Abstract No. 91-212578 of Japanese Publication JO 3135918 (Ajinomoto) (1991).
Tsujinaka et al., “Role of nucleosides and nucleoside mixture in Intestinal Mucosal Growth Under Parenteral Nutrition”, Nutrition (Nov.-Dec. 1993) 9(6):532-5.
Translation of Office Action mailed Jun. 1, 2004 in counterpart Japanese Patent Application No. 510442/94.
Bamat, M.K., et al; “Acylated Uridine and Cytidine and Uses Thereof”; (1989); Patent No. WO/8903837; (Abstract not Available).
Kypson, J. et al; “Effects of Uridine and Indosine on Glucose Metabolism in Skeletal Muscle and Activated Lipolysis in Adipose Tissue”;The Journal of Pharmacology and Experimental Therapeutics; vol. 199, No. 3; pp. 565-574; XP-008033089 (1976).
Nelson, K.A., et al; “The Cancer Anorexia-Cachexia Syndrome”;Journal of Clinical Oncology; vol. 12, No. 1; pp. 213-225; XP-002054945 (1994).
Bruera, E.; “Clinical Management of Anorexia and Cachexia in Patients with Advanced Cancer”;Oncology; vol. 49, No. Suppl 2; pp. 35-42; XP-001037960 (1992).
Tisdale, M.J.; “Cancer Cachexia”;Anti-Cancer Drugs, Rapid Communications, Oxford Ltd.; vol. 4, No. 2; pp. 115-125; XP-009023231 (1993).
Berkow, R.; “The Merck Manual of Diagnosis and Therapy, 15thed.”;Merck Sharp&Dohme Research Laboratories; pp. 907-911 (1987); XP-002276510.
Ogoshi, S., et al; “Effects of Total Parenteral Nutrition with Nucleoside and Nucleotide Mixture on D-Galactosamine-Induced Liver Injury in Rats”;Journal of Parenteral and Enteral Nutrition; vol. 12, No. 1; pp. 53-57 (1988); XP-008029611.
Wang, J., et al; “Studies on the Hepatotoxicity of Galactosamine/Endotoxin or Galactosamine/TNF in the Perfused Mouse Liver”;Biochemical Pharmacology, vol. 39, No. 2, pp. 267-270 (1990); XP-001189750.
Yokoyama, H., et al; “A Nucleoside Mixture and its Sparing Effect onDe NovoPurine Nucleotide Synthesis”;Advances in Experimental Medicine and Biology(1994), 370(Purin and Pyrimidine Metabolism in Man VIII, pp. 541-544; XP-008029609.
Kambara, Y., et al; Chemical Abstracts Service, Columbus, OH; “The Effect of Nucleosides and Nucleotides on Liver Regeneration”; Database Accession No. 108:185605; XP-002276511 (Abstract).
Bushma, M. et al.; U.S. National Library of Medicine (NLM); Bethesda, MD; (1979); “The Effect of Cytidine and Uridine on Liver Regeneration in Rats Poisioned by Carbon Tetrachloride”; Database Accession No. NLM519007; XP-002276512 (Abstract).
MacDonald, J.R., et al; Biosciences Information Service, Philadelphia, PA, (1987); “Inhibition of Galactosamine Cytotoxicity in an In-Vivo-In-Vitro Hepatocellular Toxicity Model”; Database Accession No. PREV198784072284; XP-002276513 (Abstract).
Takeda, S. et al; Biosciences Information Service, Philadelphia, PA; (1985); “Pharmacological Studies on Schizandra Fruits 3. Effects of Wuweizisu C.A. Lignan Component of Schizandra Fruits on Experimental Liver Injuries in Rats”; Database Accession No. PREV198580043139; XP-002276514 (Abstract).
Decker, K. et al; “Galactosamine Induced Livery Injury”;Progress in Liver Diseases; (1972); vol. 4, pp. 183-199; XP-008029633.
Patent Abstracts of Japan, vol. 017, No. 270; May 26, 1993; JP 05 009121 A (Otsuka Pharmaceut Factory Inc); Jan. 19, 1993 (Abstract).
Tsujinaka et al.; “Role
Bamat Michael K.
Hiltbrand Bradley M.
von Borstel Reid W.
Nixon & Vanderhye
Peselev Elli
Wellstat Therapeutics Corporation
LandOfFree
Pyrimidine nucleotide precursors for treatment of systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine nucleotide precursors for treatment of systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine nucleotide precursors for treatment of systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864196